Scholar Rock Holding Corporation received FDA approval for its drug ISEMBYLD (apitegromab) to treat spinal muscular atrophy (SMA) in patients aged 2 years and older. This approval opens a market opportunity exceeding $2 billion, with potential growth into younger patients, subcutaneous versions, and new diseases like facioscapulohumeral muscular dystrophy (FSHD). The company plans to resubmit its marketing authorization application in Europe and file for approval in Japan by the end of 2026, supported by a validated manufacturing facility. Scholar Rock currently holds $492.1 million in cash to fund operations through the second half of 2027 but may raise additional capital as commercialization progresses. Pricing and reimbursement remain key risks to watch.
Scholar Rock's recent FDA approval for its SMA drug is the subject, with Pluang's health sector data providing market context. As of Sep 16, 2026 02:01 WIB, among 91 priced US health-sector stocks on Pluang, 24 advanced while 66 declined. Notable movers include BBIO at USD 68.51 with a -5.35% change, NBIX at USD 149.47 down 4.93%, and FLNA at USD 0.69 falling 4.66%.
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
Trading in all issues of GoldCoast Resource Corp. (symbol GCR) has resumed at 8:00 AM ET following a temporary halt imposed by the Canadian Investment Regulatory Organization (CIRO). Such halts are used to maintain fair and orderly markets. CIRO over...
Equity Bancshares director Leon Borck increased his stake by purchasing 380 shares at $48.78 each, signaling confidence after the company reported strong Q3 results. The bank posted a net income of $26.8 million and core earnings of $1.40 per diluted...
